BIM
SGNT

BlackRock Investment Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

BlackRock Investment Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-119,989
Closed -$1.8M – 4065
2016
Q2 		$1.8M Buy
119,989
+34,214
+40% +$440K ﹤0.01% 2191
2016
Q1 		$1.04M Sell
85,775
-30
-0% -$421 ﹤0.01% 2456
2015
Q4 		$1.36M Buy
85,805
+1,170
+1% +$18.4K ﹤0.01% 2357
2015
Q3 		$1.3M Sell
84,635
-321
-0.4% -$6.94K ﹤0.01% 2407
2015
Q2 		$2.06M Buy
84,956
+10,208
+14% +$245K ﹤0.01% 2203
2015
Q1 		$1.74M Buy
74,748
+902
+1% +$23.9K ﹤0.01% 2134
2014
Q4 		$1.85M Sell
73,846
-1,068
-1% -$31.3K ﹤0.01% 2091
2014
Q3 		$2.33M Buy
74,914
+1,877
+3% +$50.8K ﹤0.01% 1885
2014
Q2 		$1.89M Buy
73,037
+20,825
+40% +$463K ﹤0.01% 2111
2014
Q1 		$1.22M Buy
52,212
+828
+2% +$18.1K ﹤0.01% 2370
2013
Q4 		$1.3M Buy
51,384
+502
+1% +$11.3K ﹤0.01% 2313
2013
Q3 		$1.04M Buy
50,882
+8,063
+19% +$180K ﹤0.01% 2412
2013
Q2 		$898K Buy
+42,819
New +$765K ﹤0.01% 2447

BlackRock Investment Management's SGNT Position: Q3 2016 in Review

BlackRock Investment Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 119,989 shares — an estimated $1.8M sold.

BlackRock Investment Management first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $2.33M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.

  • BlackRock Investment Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 119,989 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $1.8M.
  • BlackRock Investment Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
  • BlackRock Investment Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $2.33M in Q3 2014.
  • 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.

Based on BlackRock Investment Management's 13F filing for Q3 2016, filed 8 Nov 2016.